A Phase 2/3 interventional study of AMG 531 in Immune (Idiopathic) Thrombocytopenic Purpura (ITP), sponsored by Kyowa Kirin Co., Ltd.. Completed at 13 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2020-01-21.
Sponsored by Kyowa Kirin Co., Ltd. · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies testing romiplostim in Purpura, Thrombocytopenic — 1 open to participants now, 1 under way, none of them phase 3. romiplostim · Purpura, Thrombocytopenic.
Among the 11 studies testing romiplostim in Purpura, Thrombocytopenic, this one is the 8th largest by enrollment, is one of 3 that started in 2006, is the only one in phase 2/3, and was the 7th registered.
32 studies on the registry are indexed under Purpura, Thrombocytopenic; 6 are open to participants now.
Browse Purpura, Thrombocytopenic studies →1 of the 11 studies testing romiplostim in Purpura, Thrombocytopenic is open now, in 1 country. Recruiting first, the newest first:
The First Affiliated Hospital of Soochow University · Sites in China
Ages 18+
By country, each count listing its studies:
romiplostim: first FDA approval 2008 (NPLATE), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →
Of the 4 Purpura, Thrombocytopenic studies recruiting now, 3 set no upper age limit and none stop at 75 or younger; 1 takes children under 18; none take healthy volunteers.
This study: 20 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 4 · Phase 3 7
First in 2002; this study’s year is marked. 3 started in 2006.
This study's enrollment of 44 is below the median of 54 across 22 interventional studies indexed under Purpura, Thrombocytopenic.
Median enrollment 62 across the 11 interventional studies. Of the 10 that completed or were terminated, 7 (70%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 11 have an industry lead sponsor. The 3 most frequent:
Kyowa Kirin Co., Ltd. is the lead sponsor of 159 studies on the registry; 8 are open to participants now.
Kyowa Kirin Co., Ltd. has 2 studies filed under Purpura, Thrombocytopenic — fewer than ten, so there is no comparison to draw.
1 of the studies testing romiplostim in Purpura, Thrombocytopenic that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07612319The First Affiliated Hospital of Soochow UniversityRomiplostim for Oral TPO-RA Resistant ITP | 2027-09 |
Add it to your calendar (.ics) → With an account.
Among the 11 studies testing romiplostim in Purpura, Thrombocytopenic, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the safety and efficacy of long term dosing of AMG 531 in thrombocytopenic Japanese subjects with ITP.
It is anticipated that AMG 531 will be a safe and well tolerated in long term treatment and that AMG 531 will effectively raise and maintain platelet counts to a desired therapeutic range, when individual dose adjustments based on platelet counts are permitted.
This study is available to subjects who have completed any previous AMG 531 ITP study in Japan and meet the eligibility criteria of this study.
Romiplostim was administered by subcutaneous (SC) injection once per week. If subjects entered the extension study within 12 weeks from the last investigational product administration in the previous study and had shown an increase in platelet counts ≥ 20 x 109/L from baseline at least once during the 13-week treatment period (excluding 4 weeks after receiving rescue medication), they were treated with romiplostim at the same weekly dose (last dose on study) received in the previous study. Otherwise, subjects were treated with romiplostim at a starting dose of 3 μg/kg. Dose adjustment based on platelet counts was allowed throughout the treatment period to allow subjects to maintain platelet counts in the target range of ≥ 50 to ≤ 200 x 109/L, up to a maximum permitted dose of 10 μg/kg.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biological: AMG 531
AMG 531 will be administered by SC injection once per week from Week 1 (Day 1). The maximum permitted dose of AMG 531 is 10 μg/kg. AMG 531 will be supplied as a sterile, white, preservative-free, lyophilized powder in 5 mL glass vials containing 0.6 mg of protein per vial, and a protein concentration of 0.5 mg/mL when reconstituted with 1.2 mL of sterile water for injection.
Also known as: Romiplostim
Percentage of Participants With Adverse Events Including Clinically Significant Changes in Laboratory Values.
Subjects who reported at least 1 adverse event after beginning treatment with romiplostim in this study
Time frame: Through study completion, the median treatment duration (time between first dose and last dose) was 146.0 weeks (range: 12 to 243 weeks)
Incidence of Anti AMG 531 Antibody Formation
Subjects with positive anti-AMG 531 antibodies (either to the peptide portion of AMG 531 or to the intact molecule) and antibodies that cross-react with endogenous thrombopoietin (TPO)
Time frame: Through study completion, the median treatment duration (time between first dose and last dose) was 146.0 weeks (range: 12 to 243 weeks)
Incidence of Platelet Response (Platelet Response is Defined as a Doubling of Baseline Platelet Counts and More Than 50 x 10^9/L; Baseline Platelet Counts is That Obtained in the Previous Study)
Time frame: Through study completion, the median treatment duration (time between first dose and last dose) was 146.0 weeks (range: 12 to 243 weeks)
Percentage of Subjects Able to Reduce or Discontinue Their Concurrent ITP Therapies (for Subjects That Are Receiving Oral Corticosteroids at a Constant Dose and Schedule at the Screening Visit)
Time frame: Through study completion, the median treatment duration (time between first dose and last dose) was 146.0 weeks (range: 12 to 243 weeks)
Change From Baseline in Patient-reported Outcome (PRO) Endpoints at Each Time Point (Baseline PRO is Obtained at Day 1 Predose)
Short Form 36 (SF-36): The SF-36 has 36 questions with 8 domains: Physical Functioning, Role Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role Emotional, and Mental Health. In addition to deriving a score for each of the domains, the SF-36 generates 2 summary scores: a physical component summary (PCS) and a mental component summary (MCS). These 8 domains and 2 summary scores are scored from 0 to 100, with higher scores indicating better health status. The official version in Japanese was used in this study. Euroqol-5 Dimensions (EQ-5D): The EQ-5D is a patient-completed, multidimensional measure of HRQOL. EQ-5D index values range from -0.59 to 1.00. The EQ-5D visual analogue scale (VAS) records the respondents' self-rated health status on a vertical graduated (0 to 100) visual analogue scale. Higher EQ-5D Index and VAS scores represent better health status. The official version in Japanese was used in this study.
Time frame: By Week 48
Subjects who had completed any previous romiplostim ITP study in Japan (Studies 20050162/NCT00305435 or 20060216/NCT00603642) were eligible to screen for this study. The study began in October 2006 and continued until romiplostim was commercially available in Japan.
| Milestone | AMG 531 |
|---|---|
| Started | 44 |
| Completed | 35 |
| Not completed | 9 |
| Withdrew: Withdrawal by subject | 6 |
| Withdrew: Administrative decision | 3 |
Subjects who reported at least 1 adverse event after beginning treatment with romiplostim in this study
| percentage of participants | AMG 531 |
|---|---|
| Percentage of Participants With Adverse Events Including Clinically Significant Changes in Laboratory Values. | 100 |
Subjects with positive anti-AMG 531 antibodies (either to the peptide portion of AMG 531 or to the intact molecule) and antibodies that cross-react with endogenous thrombopoietin (TPO)
| percentage of participants | AMG 531 |
|---|---|
| Positive for romiplostim-neutralizing antibodies | 0 |
| Positive for TPO-neutralizing antibodies | 0 |
| percentage of participants | AMG 531 |
|---|---|
| Incidence of Platelet Response (Platelet Response is Defined as a Doubling of Baseline Platelet Counts and More Than 50 x 10^9/L; Baseline Platelet Counts is That Obtained in the Previous Study) | 95.5 (84.5 to 99.4) |
| percentage of participants | AMG 531 |
|---|---|
| Percentage of Subjects Able to Reduce or Discontinue Their Concurrent ITP Therapies (for Subjects That Are Receiving Oral Corticosteroids at a Constant Dose and Schedule at the Screening Visit) | 100 |
Short Form 36 (SF-36): The SF-36 has 36 questions with 8 domains: Physical Functioning, Role Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role Emotional, and Mental Health. In addition to deriving a score for each of the domains, the SF-36 generates 2 summary scores: a physical component summary (PCS) and a mental component summary (MCS). These 8 domains and 2 summary scores are scored from 0 to 100, with higher scores indicating better health status. The official version in Japanese was used in this study. Euroqol-5 Dimensions (EQ-5D): The EQ-5D is a patient-completed, multidimensional measure of HRQOL. EQ-5D index values range from -0.59 to 1.00. The EQ-5D visual analogue scale (VAS) records the respondents' self-rated health status on a vertical graduated (0 to 100) visual analogue scale. Higher EQ-5D Index and VAS scores represent better health status. The official version in Japanese was used in this study.
| score on a scale | AMG 531 |
|---|---|
| Change in EQ-5D Index score at Week 48 | 0.02 ± 0.12 |
| Change in EQ-5D VAS score at Week 48 | 6.13 ± 16.48 |
| Change in SF-36 physical functioning at Week 48 | 0.68 ± 7.19 |
| Change in SF-36 role physical at Week 48 | 2.30 ± 10.43 |
| Change in SF-36 bodily pain at Week 48 | -0.87 ± 13.42 |
| Change in SF-36 General Health Perception at W48 | 1.30 ± 5.14 |
| Change in SF-36 Vitality at Week 48 | 1.12 ± 8.42 |
| Change in SF-36 Social Functioning at Week 48 | 1.22 ± 8.56 |
| Change in SF-36 Role Emotional at Week 48 | 1.84 ± 12.82 |
| Change in SF-36 Mental Health at Week 48 | -1.42 ± 9.04 |
| Change in SF-36 Physical Component at Week 48 | 1.13 ± 6.85 |
| Change in SF-36 Mental Component at Week 48 | 0.33 ± 9.19 |
Collected over The duration of treatment in this study ranged from 12 to 243 weeks; the median (Q1, Q3) duration of treatment in this study was 146.0 (119.5, 166.0) weeks.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| AMG 531 | 0/44 (0%) | 12/44 (27.3%) | 44/44 (100%) |
| Event | AMG 531 |
|---|---|
| Haemorrhagic AnaemiaBlood and lymphatic system disorders | 1/44 |
| ThrombocytopeniaBlood and lymphatic system disorders | 1/44 |
| ArrhythmiaCardiac disorders | 1/44 |
| Colonic polypGastrointestinal disorders | 1/44 |
| MelaenaGastrointestinal disorders | 1/44 |
| Mouth HaemorrhageGastrointestinal disorders | 1/44 |
| Feeling AbnormalGeneral disorders | 1/44 |
| PyrexiaGeneral disorders | 1/44 |
| CholelithiasisHepatobiliary disorders | 1/44 |
| AppendicitisInfections and infestations | 1/44 |
| Event | AMG 531 |
|---|---|
| NasopharyngitisInfections and infestations | 35/44 |
| HeadacheNervous system disorders | 19/44 |
| Back PainMusculoskeletal and connective tissue disorders | 12/44 |
| ContusionInjury, poisoning and procedural complications | 9/44 |
| VertigoEar and labyrinth disorders | 8/44 |
| Abdominal Pain UpperGastrointestinal disorders | 8/44 |
| MalaiseGeneral disorders | 8/44 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 8/44 |
| Pain In ExtremityMusculoskeletal and connective tissue disorders | 8/44 |
| DiarrhoeaGastrointestinal disorders | 7/44 |
| Age, Continuous(years) | AMG 531 |
|---|---|
| Mean | 54.9 ± 12.9 |
| Sex: Female, Male(Participants) | AMG 531 |
|---|---|
| Female | 31 |
| Male | 13 |
| Race (NIH/OMB)(Participants) | AMG 531 |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 44 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 0 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Region of Enrollment(participants) | AMG 531 |
|---|---|
| Japan | 44 |
The record gives a start of Nov 2006, a primary completion of Jul 2011 and a completion of Sep 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2020, 8 years 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Romiplostim